Kano Therapeutics develops single-stranded DNA for targeted gene correction.
Kano Therapeutics has raised $5.0M in total funding. The most recent round was Seed. The last funding was announced in August 2024.
Kano Therapeutics's investors include Vsquared Ventures, Engine Ventures, Taihill Venture, Metaplanet, Amino Collective.
Kano Therapeutics is headquartered in Cambridge, United States.
Kano Therapeutics develops single-stranded DNA for targeted gene correction.
Kano Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kano Therapeutics — Funding & Investors." VCBacked, August 12, 2024, https://www.vcbacked.co/company/kano-therapeutics. Accessed July 21, 2026.
VCBacked. (2024). Kano Therapeutics — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/kano-therapeutics
{{cite web |title=Kano Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kano-therapeutics |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated